Report Highlights
The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.
Report Includes
- 34 data tables and 34 additional tables
- An overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
- Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
- In-depth information (facts and figures) pertaining to the major factors influencing the market, including growth trends, upcoming technologies and future prospects
- An estimate of the actual market size, a revenue forecast for the market, and a market share analysis based on product, technology, disease type, application, distribution channel and region
- A discussion of the applications for treatment and therapy technologies
- Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market
- A review of patent activity pertaining to applications for neurodegenerative disorders in the pharmaceutical and biotechnology markets
- Coverage of recent mergers and acquisitions (M&A) activity, venture fundings and other developments affecting the global market
- An analysis of the competitive landscape based on recent developments, segmental revenues and operational integration of the leading companies
- Profiles of the major players in the industry
Report Scope
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.
This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2022 | ||||||||||||||||||||||
| Forecast period considered | 2023-2028 | ||||||||||||||||||||||
| Base year market size | $32.0 billion | ||||||||||||||||||||||
| Market size forecast | $57.2 billion | ||||||||||||||||||||||
| Growth rate | CAGR of 10.2% for the forecast period of 2023-2028 | ||||||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||||||
| Segments covered | Technology, Disease Type, Disease, Distributive Channel, | ||||||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
- Increasing Prevalence of Neurological Disorders including Progressive Ataxia and Weakness Disorders and Awareness
- Technological advancements and product launch
- Increasing Expenditures for Health Care and investments for treatment for syndrome of Progressive Ataxia and Weakness Disorders
- Rise in alcohol and drug usage
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
Related Reports
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Global Markets for Bioengineered Protein Drugs
The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Immunotherapy Drugs: Global Markets
The global market for immunotherapy drugs should grow from $139.8 billion in 2020 to $204.4 billion by 2025, at compound annual growth rate (CAGR) of 7.9% for the period of 2020-2025.
Global Markets for Enzyme Inhibitors
The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More